Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Products under Development by Stage of Development | 7 | 1 |
| Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Products under Development by Therapy Area | 8 | 1 |
| Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Products under Development by Indication | 9 | 1 |
| Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Products under Development by Companies | 12 | 2 |
| Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Products under Development by Universities/Institutes | 14 | 2 |
| Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Therapeutics Assessment | 16 | 6 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Companies Involved in Therapeutics Development | 22 | 1 |
| Cyclacel Pharmaceuticals, Inc. | 22 | 1 |
| Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Drug Profiles | 23 | 10 |
| CT-526 Drug Profile | 23 | 1 |
| CYC-065 Drug Profile | 24 | 3 |
| sapacitabine + seliciclib Drug Profile | 27 | 3 |
| Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease Drug Profile | 30 | 1 |
| Synthetic Peptide to Inhibit CDK5 for CNS and Metabolic Disorders Drug Profile | 31 | 1 |
| TFP-5 Drug Profile | 32 | 1 |
| Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Dormant Projects | 33 | 1 |
| Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Featured News &Press Releases | 34 | 13 |
| Jun 06, 2016: Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO | 34 | 1 |
| May 19, 2016: Cyclacel s Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting | 35 | 1 |
| Apr 18, 2016: Cyclacel s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors | 36 | 1 |
| Dec 14, 2015: Molecular Basis for Development of Cyclacel s CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium | 37 | 1 |
| Nov 23, 2015: CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models | 38 | 1 |
| Nov 09, 2015: Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference | 38 | 1 |
| Oct 26, 2015: Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference | 39 | 1 |
| Oct 22, 2015: Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors | 40 | 1 |
| Sep 17, 2015: Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas | 40 | 1 |
| Apr 20, 2015: Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds | 41 | 2 |
| Mar 20, 2015: Cyclacel's CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015 | 43 | 1 |
| Sep 18, 2014: Cyclacel's CYC065 CDK Inhibitor Demonstrates Therapeutic Potential in Acute Leukemias With Mixed Lineage Leukemia (MLL) Rearrangements | 43 | 1 |
| Sep 10, 2014: Cyclacel Announces Abstract Selected for Presentation at Society of Hematologic Oncology Annual Meeting | 44 | 1 |
| Apr 09, 2013: Cyclacel Pharma Presents Data On Combination Potential Of Sapacitabine And Seliciclib At AACR Annual Meeting 2013 | 44 | 2 |
| Apr 07, 2013: New Drug Combination Shows Efficacy Against Incurable Solid Tumors And BRCA mutations, Study Finds | 46 | 1 |
| Appendix | 47 | 2 |
| Methodology | 47 | 1 |
| Coverage | 47 | 1 |
| Secondary Research | 47 | 1 |
| Primary Research | 47 | 1 |
| Expert Panel Validation | 47 | 1 |
| Contact Us | 47 | 1 |
| Disclaimer | 48 | 1 |